Your browser doesn't support javascript.
loading
Engineering IscB to develop highly efficient miniature editing tools in mammalian cells and embryos.
Xue, Niannian; Hong, Dishan; Zhang, Dan; Wang, Qian; Zhang, Shun; Yang, Lei; Chen, Xi; Li, Yongmei; Han, Honghui; Hu, Chunyi; Liu, Mingyao; Song, Gaojie; Guan, Yuting; Wang, Liren; Zhu, Yifan; Li, Dali.
Affiliation
  • Xue N; Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
  • Hong D; Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
  • Zhang D; Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
  • Wang Q; Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
  • Zhang S; Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
  • Yang L; Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
  • Chen X; Bioray Laboratories Inc., Shanghai, China.
  • Li Y; Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
  • Han H; Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
  • Hu C; Department of Biological Sciences, Department of Biochemistry, Precision Medicine Translational Research Programme (TRP), National University of Singapore, Singapore.
  • Liu M; Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China; Bioray Laboratories Inc., Shanghai, China.
  • Song G; Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
  • Guan Y; Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
  • Wang L; Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China. Electronic address: lrwang@bio.ecnu.edu.cn.
  • Zhu Y; Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China. Electronic address: yfzhu@bio.ecnu.edu.cn.
  • Li D; Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China. Electronic address: dlli@bio.ecnu.edu.cn.
Mol Cell ; 84(16): 3128-3140.e4, 2024 Aug 22.
Article in En | MEDLINE | ID: mdl-39096898
ABSTRACT
The IscB proteins, as the ancestors of Cas9 endonuclease, hold great promise due to their small size and potential for diverse genome editing. However, their activity in mammalian cells is unsatisfactory. By introducing three residual substitutions in IscB, we observed an average 7.5-fold increase in activity. Through fusing a sequence-non-specific DNA-binding protein domain, the eIscB-D variant achieved higher editing efficiency, with a maximum of 91.3%. Moreover, engineered ωRNA was generated with a 20% reduction in length and slightly increased efficiency. The engineered eIscB-D/eωRNA system showed an average 20.2-fold increase in activity compared with the original IscB. Furthermore, we successfully adapted eIscB-D for highly efficient cytosine and adenine base editing. Notably, eIscB-D is highly active in mouse cell lines and embryos, enabling the efficient generation of disease models through mRNARNA injection. Our study suggests that these miniature genome-editing tools have great potential for diverse applications.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: CRISPR-Cas Systems / Gene Editing Limits: Animals / Humans Language: En Journal: Mol Cell / Mol. cell / Molecular cell Journal subject: BIOLOGIA MOLECULAR Year: 2024 Document type: Article Affiliation country: China Country of publication: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: CRISPR-Cas Systems / Gene Editing Limits: Animals / Humans Language: En Journal: Mol Cell / Mol. cell / Molecular cell Journal subject: BIOLOGIA MOLECULAR Year: 2024 Document type: Article Affiliation country: China Country of publication: Estados Unidos